Crinetics Pharmaceuticals (CRNX) Insider Trading & Ownership $57.32 +0.55 (+0.97%) (As of 01:15 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$26.31 M Get CRNX Insider Trade Alerts Want to know when executives and insiders are buying or selling Crinetics Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CRNX Insider Buying and Selling by Quarter Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Crinetics Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/22/2024Jeff E KnightCOOSell501$56.52$28,316.52 10/3/2024Dana PizzutiInsiderSell14,375$54.63$785,306.25 9/26/2024Marc WilsonCFOSell25,000$51.11$1,277,750.00 9/25/2024Josh GottheimerU.S. Congress Member (D-NJ)Buy$50.45$1,001 - $15,0009/10/2024Stephen F BetzInsiderSell1,035$51.50$53,302.50 8/26/2024Stephen F BetzInsiderSell3,000$53.19$159,570.00 7/25/2024Marc WilsonCFOSell19,056$53.88$1,026,737.28 Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link.7/25/2024Stephen F BetzInsiderSell3,000$53.43$160,290.00 7/15/2024Jeff E KnightCOOSell27,000$55.00$1,485,000.00 7/15/2024Marc WilsonCFOSell25,000$55.00$1,375,000.00 7/10/2024Stephen F BetzInsiderSell3,000$48.55$145,650.00 7/5/2024James HassardInsiderSell15,000$44.08$661,200.00 7/3/2024Dana PizzutiInsiderSell14,375$44.87$645,006.25 6/28/2024Marc WilsonCFOSell32,129$43.61$1,401,145.69 6/26/2024Jeff E KnightCOOSell956$44.38$42,427.28 6/24/2024Dana PizzutiInsiderSell9,500$45.73$434,435.00 6/21/2024James HassardInsiderSell15,000$44.66$669,900.00 6/10/2024Stephen F BetzInsiderSell3,000$43.86$131,580.00 5/28/2024Stephen F BetzInsiderSell3,000$47.49$142,470.00 5/10/2024Stephen F BetzInsiderSell3,000$49.43$148,290.00 5/8/2024Richard Scott StruthersCEOSell107,448$49.40$5,307,931.20 4/15/2024Dana PizzutiInsiderSell14,375$44.47$639,256.25 4/4/2024Richard Scott StruthersCEOSell40,951$49.17$2,013,560.67 3/28/2024Stephanie OkeyDirectorSell17,500$46.38$811,650.00 3/22/2024Jeff E KnightCOOSell32,359$44.31$1,433,827.29 3/20/2024Dana PizzutiInsiderSell15,089$44.06$664,821.34 3/20/2024Matthew K FustDirectorSell60,000$44.14$2,648,400.00 3/19/2024Marc WilsonCFOSell6,942$42.91$297,881.22 1/25/2024Stephen F BetzInsiderSell3,000$37.26$111,780.00 1/10/2024Stephen F BetzInsiderSell3,000$37.65$112,950.00 1/3/2024Dana PizzutiInsiderSell14,375$35.00$503,125.00 1/2/2024Marc WilsonCFOSell10,000$35.47$354,700.00 12/26/2023Stephen F BetzInsiderSell3,000$35.89$107,670.00 12/21/2023Dana PizzutiInsiderSell9,583$34.57$331,284.31 12/11/2023Stephen F BetzInsiderSell3,000$32.87$98,610.00 11/27/2023Stephen F BetzInsiderSell3,000$31.84$95,520.00 (Data available from 1/1/2013 forward) CRNX Insider Trading Activity - Frequently Asked Questions Who is on Crinetics Pharmaceuticals's Insider Roster? The list of insiders at Crinetics Pharmaceuticals includes Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, James Hassard, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey, and Stephen F Betz. Learn more on insiders at CRNX. What percentage of Crinetics Pharmaceuticals stock is owned by insiders? 6.00% of Crinetics Pharmaceuticals stock is owned by insiders. Learn more on CRNX's insider holdings. Which Crinetics Pharmaceuticals insiders have been buying company stock? The following insider purchased CRNX shares in the last 24 months: Coelho Rogerio Vivaldi ($110,300.00). How much insider buying is happening at Crinetics Pharmaceuticals? Insiders have purchased a total of 5,000 CRNX shares in the last 24 months for a total of $110,300.00 bought. Which Crinetics Pharmaceuticals insiders have been selling company stock? The following insiders have sold CRNX shares in the last 24 months: Alan Seth Krasner ($210,000.00), Dana Pizzuti ($4,135,858.20), James Hassard ($1,331,100.00), Jeff E Knight ($2,989,571.09), Marc Wilson ($6,638,226.53), Matthew K Fust ($2,648,400.00), Richard Scott Struthers ($15,225,126.50), Stephanie Okey ($811,650.00), and Stephen F Betz ($1,805,373.86). How much insider selling is happening at Crinetics Pharmaceuticals? Insiders have sold a total of 922,020 Crinetics Pharmaceuticals shares in the last 24 months for a total of $35,795,306.18 sold. Which members of congress are trading Crinetics Pharmaceuticals? Josh Gottheimer (D-NJ) has bought shares of Crinetics Pharmaceuticals in the last year totaling $8,000. Crinetics Pharmaceuticals Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 61)Founder, President, CEO & Director Compensation: $978.34kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Compensation: $672.66kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Compensation: $642.25kMr. Jeff E. Knight (Age 53)Chief Operating Officer Compensation: $657.31k3 recent tradesDr. Alan S. Krasner M.D. (Age 61)Chief Endocrinologist Compensation: $653.92kMr. James Hassard (Age 58)Chief Commercial Officer Compensation: $623.5k2 recent tradesMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerMr. Kevin CappsHead of Intellectual PropertyMr. Chris Robillard M.B.A.Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies Teva Pharmaceutical Industries Insider Trading BeiGene Insider Trading Moderna Insider Trading Viatris Insider Trading Summit Therapeutics Insider Trading Genmab A/S Insider Trading Vaxcyte Insider Trading Catalent Insider Trading Sarepta Therapeutics Insider Trading Revolution Medicines Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:CRNX) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
